ALC Stock - Alcon Inc.
Unlock GoAI Insights for ALC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.91B | $9.46B | $8.72B | $8.29B | $6.83B |
| Gross Profit | $5.51B | $5.25B | $4.75B | $4.65B | $2.94B |
| Gross Margin | 55.6% | 55.5% | 54.5% | 56.1% | 43.0% |
| Operating Income | $1.41B | $1.04B | $672.00M | $580.00M | $-482,000,000 |
| Net Income | $1.02B | $974.00M | $335.00M | $376.00M | $-531,000,000 |
| Net Margin | 10.3% | 10.3% | 3.8% | 4.5% | -7.8% |
| EPS | $2.06 | $1.98 | $0.68 | $0.77 | $-1.09 |
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | BofA Securities | Downgrade | Underperform | $75 |
| August 21st 2025 | JP Morgan | Downgrade | Neutral | - |
| May 20th 2025 | Deutsche Bank | Downgrade | Hold | - |
| May 14th 2025 | BTIG Research | Reiterated | Buy | $99← $102 |
| March 28th 2025 | Needham | Reiterated | Buy | $110← $107 |
| March 25th 2025 | BofA Securities | Upgrade | Buy | - |
| January 24th 2025 | Needham | Reiterated | Buy | $106← $108 |
| January 10th 2025 | Redburn Atlantic | Upgrade | Buy | - |
| December 17th 2024 | Needham | Reiterated | Buy | $108← $103 |
| November 12th 2024 | Needham | Reiterated | Buy | - |
| October 10th 2024 | Redburn Atlantic | Upgrade | Neutral | - |
| September 10th 2024 | RBC Capital Mkts | Upgrade | Outperform | - |
| July 15th 2024 | Morgan Stanley | Upgrade | Equal Weight | $85← $65 |
| May 15th 2024 | Oppenheimer | Upgrade | Outperform | $103 |
| April 10th 2024 | Goldman | Initiation | Buy | $100 |
Earnings History & Surprises
ALCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $0.81 | — | — | — |
Q4 2025 | Nov 11, 2025 | $0.77 | $0.79 | +2.6% | ✓ BEAT |
Q3 2025 | Aug 19, 2025 | $0.71 | $0.76 | +7.0% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $0.76 | $0.73 | -3.9% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $0.70 | $0.72 | +2.9% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.72 | $0.81 | +12.5% | ✓ BEAT |
Q3 2024 | Aug 20, 2024 | $0.74 | $0.74 | 0.0% | = MET |
Q2 2024 | May 13, 2024 | $0.72 | $0.78 | +8.3% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.68 | $0.69 | +1.5% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $0.67 | $0.66 | -1.5% | ✗ MISS |
Q3 2023 | Aug 15, 2023 | $0.62 | $0.69 | +11.3% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $0.60 | $0.70 | +16.7% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $0.42 | $0.42 | 0.0% | = MET |
Q4 2022 | Nov 15, 2022 | $0.48 | $0.50 | +4.2% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $0.55 | $0.63 | +14.5% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.52 | $0.68 | +30.8% | ✓ BEAT |
Q1 2022 | Feb 15, 2022 | $0.49 | $0.56 | +14.3% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $0.49 | $0.54 | +10.2% | ✓ BEAT |
Q3 2021 | Aug 17, 2021 | $0.43 | $0.56 | +30.2% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $0.44 | $0.49 | +11.4% | ✓ BEAT |
Latest News
Alcon Exercises Merger Rights, Forcing STAAR Surgical To Adjourn Shareholder Vote To January 6, 2026
📉 NegativeBroadwood Partners Slams Alcon–STAAR Deal, Flag Sale Process Concerns
📉 NegativeReported Earlier, Independent Proxy Firm ISS Recommends Approval Of STAAR Surgical's Merger With Alcon
📈 PositiveSTAAR Surgical gains as proxy adviser ISS supports revised Alcon deal
📈 PositiveBroadwood Slams STAAR–Alcon Deal as Flawed and Unfair to Shareholders
📉 NegativeB of A Securities Downgrades Alcon to Underperform, Lowers Price Target to $75
📉 NegativeMajor Shareholder Rejects STAAR Surgical's Sale to Alcon Despite Higher $30.75 Offer
📉 NegativeBroadwood Partners, 30.2% Stake Holders, Opposes Alcon's STAAR Surgical Acquisition; Says Calls Price Bump "Insufficient" And Sale Process Deeply Flawed
📉 NegativeSTAAR Surgical shares are trading higher after Alcon amended its merger agreement to acquire the company for $30.75 per share in cash.
📈 PositiveAlcon Enters Amended Merger Agreement For Acquisition Of STAAR Surgical, will Purchase All Outstanding STAAR Shares For $30.75/Share In Cash, Representing Additional $150M In Equity Value
📈 PositiveBTIG Reiterates Buy on Alcon, Maintains $91 Price Target
📈 PositiveBTIG Reiterates Buy on Alcon, Maintains $91 Price Target
📈 PositiveBaird Maintains Outperform on Alcon, Raises Price Target to $98
📈 PositiveNeedham Maintains Buy on Alcon, Lowers Price Target to $98
📈 PositiveAlcon shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.
📈 PositiveAlcon Sees FY25 EPS $3.05-$3.15; Sales $10.3B-$10.4B
📈 PositiveAlcon Q3 Adj. EPS $0.79 Beats $0.76 Estimate, Sales $2.589B Miss $2.603B Estimate
➖ NeutralMizuho Maintains Outperform on Alcon, Lowers Price Target to $100
➖ NeutralSTAAR Surgical Agrees With Alcon To Amend Merger Agreement To Allow Proactive Solicitation By STAAR Of Third-Party Proposals To Maximize Value For All STAAR Stockholders
📈 PositiveKeybanc Maintains Overweight on Alcon, Lowers Price Target to $91
➖ NeutralFrequently Asked Questions about ALC
What is ALC's current stock price?
What is the analyst price target for ALC?
What sector is Alcon Inc. in?
What is ALC's market cap?
Does ALC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALC for comparison